Sanofi (SNY): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Sanofi ( SNY) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.7%. By the end of trading, Sanofi rose $0.93 (1.9%) to $50.42 on average volume. Throughout the day, 2,198,159 shares of Sanofi exchanged hands as compared to its average daily volume of 1,737,500 shares. The stock ranged in a price between $49.74-$50.48 after having opened the day at $49.86 as compared to the previous trading day's close of $49.49. Other companies within the Drugs industry that increased today were: Aoxing Pharmaceutical Company ( AXN), up 15.4%, La Jolla Pharmaceutical ( LJPC), up 11.6%, Nanoviricides ( NNVC), up 10.9% and Tekmira Pharmaceuticals Corporation ( TKMR), up 8.1%.

Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $131.0 billion and is part of the health care sector. Shares are down 7.7% year to date as of the close of trading on Thursday. Currently there are 2 analysts that rate Sanofi a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the negative front, Ohr Pharmaceutical ( OHRP), down 18.9%, Galena Biopharma ( GALE), down 14.3%, Tianyin Pharmaceutical ( TPI), down 13.1% and Prana Biotechnology ( PRAN), down 10.9% , were all laggards within the drugs industry with Intercept Pharmaceuticals ( ICPT) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Investors Are Trying to Figure Out the 'Powell Put'

Investors Are Trying to Figure Out the 'Powell Put'

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know